Medidata Solutions (MDSO) PT Lowered to $75.00 at Needham & Company LLC
Other research analysts also recently issued research reports about the stock. Deutsche Bank initiated coverage on shares of Medidata Solutions in a research report on Friday, December 8th. They set a buy rating and a $78.00 price objective on the stock. SunTrust Banks restated a buy rating and set a $92.00 price objective on shares of Medidata Solutions in a research report on Friday, October 27th. Dougherty & Co upgraded shares of Medidata Solutions from a neutral rating to a buy rating and set a $75.00 price objective on the stock in a research report on Monday, November 13th. TheStreet downgraded shares of Medidata Solutions from a b rating to a c+ rating in a research report on Thursday, December 14th. Finally, Royal Bank of Canada restated a hold rating and set a $80.00 price objective on shares of Medidata Solutions in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $83.00.
Shares of Medidata Solutions (MDSO) opened at $62.48 on Friday. Medidata Solutions has a fifty-two week low of $54.36 and a fifty-two week high of $85.92. The company has a current ratio of 1.50, a quick ratio of 3.37 and a debt-to-equity ratio of 0.20. The company has a market cap of $3,807.70, a P/E ratio of 84.43, a PEG ratio of 3.49 and a beta of 1.58.
In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $66.33, for a total value of $331,650.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Rouven Bergmann sold 3,000 shares of the stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $70.00, for a total transaction of $210,000.00. Following the completion of the transaction, the chief financial officer now owns 84,775 shares in the company, valued at $5,934,250. The disclosure for this sale can be found here. Insiders sold 29,010 shares of company stock worth $1,962,206 over the last quarter. Insiders own 5.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Summit Creek Advisors LLC bought a new stake in shares of Medidata Solutions during the 4th quarter valued at $5,137,000. AMP Capital Investors Ltd bought a new stake in shares of Medidata Solutions during the 3rd quarter valued at $2,194,000. KAMES CAPITAL plc raised its position in shares of Medidata Solutions by 54.6% during the 4th quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock valued at $1,617,000 after purchasing an additional 9,012 shares during the period. Zions Bancorporation bought a new stake in shares of Medidata Solutions during the 3rd quarter valued at $256,000. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Medidata Solutions by 38.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 326,950 shares of the company’s stock valued at $25,522,000 after purchasing an additional 90,572 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.